Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DARRICK J ALAIMO

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1861455586
CMS profile
357242
Location
ROCHESTER, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$18,767.65

144 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DARRICK J ALAIMO

NPI 1861455586 · CMS profile ID 357242

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ROCHESTER, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861455586?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DARRICK J ALAIMO, NPI 1861455586, CMS profile ID 357242. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861455586?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DARRICK J ALAIMO, NPI 1861455586, CMS profile ID 357242. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861455586?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DARRICK J ALAIMO, NPI 1861455586, CMS profile ID 357242, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1861455586?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

144 matching records · $18,767.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 144 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 144.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $28.6010/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136146035 CMS
ABBVIE INC. $4.2610/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195560 CMS
Neurocrine Biosciences, Inc. $35.3210/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150818652 CMS
Lilly USA, LLC $22.0910/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136133839 CMS
ABBVIE INC. $8.8209/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195556 CMS
ABBVIE INC. $4.7209/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195558 CMS
Lundbeck LLC $20.8309/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145890157 CMS
ABBVIE INC. $6.5809/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195554 CMS
Novartis Pharmaceuticals Corporation $25.0509/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086715503 CMS
Lilly USA, LLC $26.4109/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136122890 CMS
ABBVIE INC. $30.7609/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195552 CMS
Amneal Pharmaceuticals LLC $37.5009/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139178421 CMS
PFIZER INC. $6.9909/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131941765 CMS
ARGENX US, INC. $22.7009/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142111587 CMS
Kyowa Kirin, Inc. $23.1708/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127028213 CMS
GENZYME CORPORATION $124.9908/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139650433 CMS
Genentech USA, Inc. $24.4108/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132995453 CMS
EMD Serono, Inc. $36.6308/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120258156 CMS
ABBVIE INC. $23.8508/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195550 CMS
ABBVIE INC. $13.0008/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195548 CMS
ABBVIE INC. $5.0808/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195546 CMS
JAZZ PHARMACEUTICALS INC. $21.6008/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150235682 CMS
JAZZ PHARMACEUTICALS INC. $21.6008/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150235686 CMS
Neurocrine Biosciences, Inc. $34.7408/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150819182 CMS
ABBVIE INC. $6.8408/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195544 CMS
ABBVIE INC. $9.7508/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195542 CMS
PFIZER INC. $26.0108/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131756040 CMS
Lilly USA, LLC $28.7608/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136146033 CMS
GENZYME CORPORATION $109.9907/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139650415 CMS
PFIZER INC. $26.8507/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131758858 CMS
ABBVIE INC. $9.2907/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195540 CMS
ABBVIE INC. $31.7107/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195538 CMS
ABBVIE INC. $8.1207/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195536 CMS
Lilly USA, LLC $21.6007/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136125771 CMS
ABBVIE INC. $18.1207/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195534 CMS
Biogen, Inc. $25.8707/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104809917 CMS
ABBVIE INC. $25.6107/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195532 CMS
Kyowa Kirin, Inc. $27.4607/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127028211 CMS
ABBVIE INC. $11.3007/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195530 CMS
PFIZER INC. $6.7706/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131527540 CMS
GENZYME CORPORATION $29.5706/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139650399 CMS
JAZZ PHARMACEUTICALS INC. $115.0006/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150235688 CMS
Lilly USA, LLC $25.6906/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136133837 CMS
ABBVIE INC. $7.0406/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195528 CMS
PFIZER INC. $5.6506/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131647082 CMS
UCB, Inc. $22.8206/17/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155572993 CMS
ABBVIE INC. $26.8906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195526 CMS
Alexion Pharmaceuticals, Inc. $20.3806/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093980603 CMS
ABBVIE INC. $27.0306/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195524 CMS
ABBVIE INC. $27.2206/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103195522 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,775.10 92
PY2020 $1,576.25 96
PY2021 $20,483.48 129
PY2022 $34,835.17 150
PY2023 $15,108.05 134
PY2024 $18,767.65 144
PY2025 $7,387.08 156

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $15,990.60 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $1,043.00 12/24/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292497
Principal investigator 1 Ipsen Innovation $905.80 12/24/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292499
Principal investigator 1 Ipsen Innovation $90.00 12/03/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292501
Principal investigator 1 Ipsen Innovation $2,000.00 10/30/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292491
Principal investigator 1 Ipsen Innovation $2,128.00 10/27/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292481
Principal investigator 1 Ipsen Innovation $2,716.00 10/27/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292489
Principal investigator 1 Ipsen Innovation $905.80 10/27/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292495
Principal investigator 1 Ipsen Innovation $400.00 10/17/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292487
Principal investigator 1 Ipsen Innovation $400.00 10/17/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292493
Principal investigator 1 Ipsen Innovation $43.50 10/06/2025 Non-covered Recipient Entity
Rochester Clinical Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292483
Principal investigator 1 Ipsen Innovation $43.50 10/06/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292485
Principal investigator 1 Ipsen Innovation $300.00 09/16/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292475
Principal investigator 1 Ipsen Innovation $180.00 09/16/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292477
Principal investigator 1 Ipsen Innovation $300.00 09/16/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292479
Principal investigator 1 Ipsen Innovation $79.80 08/28/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292467
Principal investigator 1 Ipsen Innovation $90.00 08/18/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292469
Principal investigator 1 Ipsen Innovation $150.00 08/18/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292471
Principal investigator 1 Ipsen Innovation $150.00 08/18/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292473
Principal investigator 1 Ipsen Innovation $300.00 07/25/2025 Non-covered Recipient Entity
Rochester Clinical Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292465
Principal investigator 1 Ipsen Innovation $79.80 06/30/2025 Non-covered Recipient Entity
Rochester Clinical Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292463
Principal investigator 1 Ipsen Innovation $1,937.60 05/30/2025 Non-covered Recipient Entity
Rochester Clinical Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292459
Principal investigator 1 Ipsen Innovation $905.80 05/30/2025 Non-covered Recipient Entity
Rochester Clinical Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292461
Principal investigator 1 Ipsen Innovation $400.00 05/21/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292453
Principal investigator 1 Ipsen Innovation $21.00 05/21/2025 Non-covered Recipient Entity
Rochester Clinical Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292455
Principal investigator 1 Ipsen Innovation $21.00 05/21/2025 Non-covered Recipient Entity
Rochester Clinical Research
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184292457
Principal investigator 1 Ipsen Innovation $400.00 04/14/2025 Non-covered Recipient Entity
Rochester Clinical Research
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184292441